Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Medication Treatments

News
Low-Dose Ketamine Reduces Alcohol Use Disorder Relapse in Trial
02/02/2022
A combination of a low dose of ketamine and psychological therapy was found to help patients with severe alcohol use disorder remain sober longer, according to findings from a recent study conducted by researchers at the University of Exeter...
A combination of a low dose of ketamine and psychological therapy was found to help patients with severe alcohol use disorder remain sober longer, according to findings from a recent study conducted by researchers at the University of Exeter...
A combination of a low dose of...
02/02/2022
Psych Congress Network
News
Ananda Gets FDA Approval to Study CBD as Adjunctive Treatment for OUD
01/25/2022
Ananda Scientific has received approval by the FDA for its investigational new drug application for a clinical trial of an investigational drug that uses CBD as an adjunctive treatment for OUD.
Ananda Scientific has received approval by the FDA for its investigational new drug application for a clinical trial of an investigational drug that uses CBD as an adjunctive treatment for OUD.
Ananda Scientific has received...
01/25/2022
Addiction Professional
News
Despite Progress, Buprenorphine Use in US Correctional Settings Falling Short
01/21/2022
Between June 2016 and May 2021, buprenorphine use in correctional settings increased 224-fold in the United States, according to a study published online in JAMA Network Open. Despite the substantial increase, buprenorphine treatment is still...
Between June 2016 and May 2021, buprenorphine use in correctional settings increased 224-fold in the United States, according to a study published online in JAMA Network Open. Despite the substantial increase, buprenorphine treatment is still...
Between June 2016 and May 2021,...
01/21/2022
Psych Congress Network
News
Recidivism Rates Drop for Inmates With OUD Treated With Buprenorphine
01/19/2022
In a study of 2 rural Massachusetts jails, risk of recidivism after leaving jail was found to be lower among those with opioid use disorder who were offered buprenorphine during their incarceration vs. those who were not.
In a study of 2 rural Massachusetts jails, risk of recidivism after leaving jail was found to be lower among those with opioid use disorder who were offered buprenorphine during their incarceration vs. those who were not.
In a study of 2 rural...
01/19/2022
Addiction Professional
News
Buprenorphine Treatment Access Equitable in Areas Where Medicaid is Prevalent
01/14/2022
In areas where Medicaid coverage is more common, providers of buprenorphine treatment are much less likely to discriminate between prospective patients with Medicaid and those with private insurance, according to a study published in Health...
In areas where Medicaid coverage is more common, providers of buprenorphine treatment are much less likely to discriminate between prospective patients with Medicaid and those with private insurance, according to a study published in Health...
In areas where Medicaid coverage...
01/14/2022
Psych Congress Network
News
University of Wyoming, CaaMTech to Study Potential of Psychedelic Compounds to Treat Addiction
12/16/2021
The University of Wyoming School of Pharmacy announced that it has formed a collaboration with CaaMTech, a Washington state-based developer of psychedelic drugs, to evaluate the company’s proprietary compounds as treatments for addiction.
The University of Wyoming School of Pharmacy announced that it has formed a collaboration with CaaMTech, a Washington state-based developer of psychedelic drugs, to evaluate the company’s proprietary compounds as treatments for addiction.
The University of Wyoming School...
12/16/2021
Addiction Professional
News
Delix Partners With NIDA to Study Ibogaine Analog to Treat Multiple SUDs
12/09/2021
Delix Therapeutics has partnered with the National Institute on Drug Abuse to study the use of its DLX-7 ibogaine analog to treat multiple substance use disorders.
Delix Therapeutics has partnered with the National Institute on Drug Abuse to study the use of its DLX-7 ibogaine analog to treat multiple substance use disorders.
Delix Therapeutics has partnered...
12/09/2021
Psych Congress Network
News
Study Shows Potential for Hospital-Based Strategies to Address Opioid Epidemic
12/06/2021
The combination of expanding hospital-based prescribing of medications for opioid use disorder and implementing addiction consult services could be the basis for a hospital-based strategy for improving life expectancy and reducing healthcare...
The combination of expanding hospital-based prescribing of medications for opioid use disorder and implementing addiction consult services could be the basis for a hospital-based strategy for improving life expectancy and reducing healthcare...
The combination of expanding...
12/06/2021
Addiction Professional
News
Increase in Take-Home Methadone Doses Doesn’t Worsen Treatment Outcomes in Study
11/05/2021
A near doubling in take-home methadone doses as a result of a COVID-19-related exemption was not associated with negative treatment outcomes in a study of patients at a clinic in Spokane County, Washington, suggesting a permanent loosening of...
A near doubling in take-home methadone doses as a result of a COVID-19-related exemption was not associated with negative treatment outcomes in a study of patients at a clinic in Spokane County, Washington, suggesting a permanent loosening of...
A near doubling in take-home...
11/05/2021
Addiction Professional
News
Stigma Around SUD Remains Pervasive Among Public—and Practitioners
11/02/2021
More than three-quarters of Americans surveyed believe that substance use disorder is not a chronic medical illness and more than half said they believe SUD is caused by bad character or lack of moral strength, according to findings from the...
More than three-quarters of Americans surveyed believe that substance use disorder is not a chronic medical illness and more than half said they believe SUD is caused by bad character or lack of moral strength, according to findings from the...
More than three-quarters of...
11/02/2021
Addiction Professional

Advertisement

Advertisement

Browse Our Other Brands

Psych NP Institute

 

Psych Congress Network

 

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement